Ressources numériques en sciences humaines et sociales OpenEdition Nos plateformes OpenEdition Books OpenEdition Journals Hypothèses Calenda Bibliothèques OpenEdition Freemium Suivez-nous

USA – FDA releases draft guidance on use-related risk analysis for combo products

The US Food and Drug Administration (FDA) has released a draft guidance outlining the purpose and content of a use-related risk analysis (URRA) for drug- and biologic-led combination products.

The URRA draft guidance is relevant for drug- and biologic-led combination products, as well as human nonprescription drug products that are part of an investigational new drug application (IND), a new drug application (NDA), or a biologics license application (BLA) or supplements to IND, NDA, or BLA applications. “A URRA is important to help identify use-related hazards associated with the user interface design of the combination product, as well as to characterize risks so they can be mitigated (such as through risk controls) or eliminated through improved product user interface design,” FDA said.

More information on the Regulatory Focus Website.


OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (19 octobre 2024). USA – FDA releases draft guidance on use-related risk analysis for combo products. ELSIBI. Consulté le 18 février 2026 à l’adresse https://doi.org/10.58079/12jag


Vous aimerez aussi...

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

This site uses Akismet to reduce spam. Learn how your comment data is processed.